Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.

Auteurs : Pérez-García JM, Gebhart G, Borrego MR, Schmid P, Marmé F, Prat A, Dalenc F, Kerrou K, Colleoni M, Braga S, Malfettone A, Sampayo-Cordero M, Cortés J, Llombart-Cussac A
Jaar : 2022
Journal : Future Oncol
Volume : 18
Pagina's : 3677-3688